News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
For Authors
Tumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice
Between the Lines
Contemporary Concepts
Journal
OncView
Podcasts
Readout 360
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
CancerNetwork® Inaugural Face-Off
Contemporary Concepts in Hematologic Oncology
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid Leukemia
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
For Authors
Tumor Board
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
| CancerNetwork® Inaugural Face-Off
| Contemporary Concepts in Hematologic Oncology
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Promising Biomarker for HPV-Related Oropharyngeal Cancer

Jul 23, 2013
Leah Lawrence

More than one-third of patients with oropharyngeal cancer were seropositive for HPV16 E6 an average of 6 years prior to their cancer diagnosis compared with less than 1% of healthy controls, a new study has found.

More than one-third of patients with oropharyngeal cancer were seropositive for HPV16 E6 an average of 6 years prior to their cancer diagnosis compared with less than 1% of healthy controls, a new study has found. In some cases, patients had seropositivity more than 10 years before their diagnosis with oropharyngeal cancer.

Sarcoid-like lesion (benign epitheloid cell reaction) in a nuchal lymph node in a case of oropharyngeal squamous cell carcinoma; source: Patho, Wikimedia Commons

HPV16 has been linked to a rapid increase in the incidence of oropharyngeal cancers worldwide. Prior research has shown that “antibody markers against HPV E6 and E7 oncoproteins should occur in response to an underlying HPV-driven neoplastic process.” Although multiple studies have validated this theory for HPV E6 antibodies, evidence is less clear for HPV16 E7 antibodies.

Researchers led by Aime R. Kreimer, PhD, of the National Cancer Institute, identified 638 participants with a variety of head and neck cancers, including oral, oropharynx, and hypopharynx/larynx cancers, and 300 patients with esophageal cancers. Pre-diagnostic plasma samples were analyzed for antibodies against HPV oncogenes E6 and E7, and several other types of HPV. Results in patients with cancers were compared with 1,599 control patients. The results were published in the Journal of Clinical Oncology.

Patients who had oropharyngeal cancer had a high adjusted odds ratio of 274 for the diagnosis of subsequent oropharyngeal cancer compared with the healthy controls (95% CI, 110–681). Seropositivity for HPV16 E6 antibodies occurred in 34.8% of patients with oropharyngeal cancer compared with 0.6% of healthy control patients. HPV16 E6 seropositivity was not associated with cancer of other sites.

Similar to prior studies, where results have been unclear, HPV16 E7 seropositivity was found in 11% of healthy control patients. However, 42.6% of patients who had HPV16 E6 positivity also had E7 seropositivity, the researchers found.

“None of the control participants or patients with oral cavity or esophageal cancer were seropositive for both HPV16 E6 and E7, but one patient with laryngeal cancer was dual positive for HPV16 E6 and E7,” the researchers wrote.

Those patients with oropharyngeal cancer who were HPV16 E6 seropositive were more likely to be never-smokers, to have a greater body mass index, and were older at the time of diagnosis. No differences were found between seropositive and seronegative patients for sex, region of Europe, and alcohol consumption.

In addition, patients who were seropositive for HPV E6 had a better prognosis. The 5-year survival was 58% for patients who were seronegative compared with 84% for patients who were seropositive.

“Further quantification of the lead time between HPV16 E6 seroconversion and cancer detection is warranted, to better understand how far in advance testing could occur,” the researchers wrote.

Related Videos
head and neck cancer
head and neck cancer
head and neck cancer
head and neck cancer
head and neck cancer
Related Content

Sintilimab Combo Reduces Recurrent Disease in Nasopharyngeal Carcinoma

June 6th 2023

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

September 15th 2017

Darolutamide Shows Potential in Treating AR-Positive Salivary Gland Cancer

June 5th 2023

Nivolumab/Ipilimumab Does Not Yield Response in Advanced HNSCC

May 5th 2023

NLRP3 Inhibitor/Nrf2 Upregulator Receives FDA FTD for Severe Oral Mucositis

April 3rd 2023

Axitinib Plus Avelumab Yields Some Responses in Adenoid Cystic Carcinoma

March 29th 2023

Sintilimab Combo Reduces Recurrent Disease in Nasopharyngeal Carcinoma

June 6th 2023

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

September 15th 2017

Darolutamide Shows Potential in Treating AR-Positive Salivary Gland Cancer

June 5th 2023

Nivolumab/Ipilimumab Does Not Yield Response in Advanced HNSCC

May 5th 2023

NLRP3 Inhibitor/Nrf2 Upregulator Receives FDA FTD for Severe Oral Mucositis

April 3rd 2023

Axitinib Plus Avelumab Yields Some Responses in Adenoid Cystic Carcinoma

March 29th 2023

Sintilimab Combo Reduces Recurrent Disease in Nasopharyngeal Carcinoma

June 6th 2023

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

September 15th 2017

Darolutamide Shows Potential in Treating AR-Positive Salivary Gland Cancer

June 5th 2023

Nivolumab/Ipilimumab Does Not Yield Response in Advanced HNSCC

May 5th 2023

NLRP3 Inhibitor/Nrf2 Upregulator Receives FDA FTD for Severe Oral Mucositis

April 3rd 2023

Axitinib Plus Avelumab Yields Some Responses in Adenoid Cystic Carcinoma

March 29th 2023
Related Content

Sintilimab plus chemoradiotherapy produces a higher 3-year distant metastasis-free survival rate vs chemoradiotherapy alone among patients with advanced nasopharyngeal carcinoma in the phase 3 CONTINUUM trial.

Sintilimab Combo Reduces Recurrent Disease in Nasopharyngeal Carcinoma

June 6th 2023
Article

Sintilimab plus chemoradiotherapy produces a higher 3-year distant metastasis-free survival rate vs chemoradiotherapy alone among patients with advanced nasopharyngeal carcinoma in the phase 3 CONTINUUM trial.


David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

September 15th 2017
Podcast

In this interview we discuss new clinical guidelines from ASTRO on the use of radiotherapy in treating oropharyngeal cancer.


With no standard treatment available, darolutamide shows potential activity among patients with androgen receptor–positive salivary gland cancer in the phase 2 DISCOVARY trial.

Darolutamide Shows Potential in Treating AR-Positive Salivary Gland Cancer

June 5th 2023
Article

With no standard treatment available, darolutamide shows potential activity among patients with androgen receptor–positive salivary gland cancer in the phase 2 DISCOVARY trial.


Investigators say that among those with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma who responded to nivolumab plus ipilimumab duration of response was not reached.

Nivolumab/Ipilimumab Does Not Yield Response in Advanced HNSCC

May 5th 2023
Article

Investigators say that among those with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma who responded to nivolumab plus ipilimumab duration of response was not reached.


In addition to granting fast track designation to RRx-001, the FDA accepts an investigational new drug application for the agent to reduce and/or prevent radiation- and chemotherapy-associated oral mucositis.

NLRP3 Inhibitor/Nrf2 Upregulator Receives FDA FTD for Severe Oral Mucositis

April 3rd 2023
Article

In addition to granting fast track designation to RRx-001, the FDA accepts an investigational new drug application for the agent to reduce and/or prevent radiation- and chemotherapy-associated oral mucositis.


Adding avelumab to VEGFR inhibitor axitinib may prolong survival and improve outcomes among patients with recurrent/metastatic adenoid cystic carcinoma.

Axitinib Plus Avelumab Yields Some Responses in Adenoid Cystic Carcinoma

March 29th 2023
Article

Adding avelumab to VEGFR inhibitor axitinib may prolong survival and improve outcomes among patients with recurrent/metastatic adenoid cystic carcinoma.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.